Comparing Glucose Health (GLUC) and Its Rivals

Glucose Health (OTCMKTS:GLUC) is one of 51 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare Glucose Health to similar companies based on the strength of its risk, profitability, valuation, dividends, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Glucose Health and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	-75.00%	N/A	N/A
Glucose Health Competitors	-42.21%	-22.72%	-7.72%

Valuation and Earnings

This table compares Glucose Health and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Glucose Health	$540,000.00	-$420,000.00	-5.71
Glucose Health Competitors	$309.39 million	-$49.38 million	-8.42

Glucose Health’s competitors have higher revenue, but lower earnings than Glucose Health. Glucose Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

15.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 20.9% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Glucose Health and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	N/A
Glucose Health Competitors	272	537	980	74	2.46

As a group, “Medicinals & botanicals” companies have a potential upside of 41.95%. Given Glucose Health’s competitors higher possible upside, analysts clearly believe Glucose Health has less favorable growth aspects than its competitors.

Volatility and Risk

Glucose Health has a beta of 3.49, suggesting that its stock price is 249% more volatile than the S&P 500. Comparatively, Glucose Health’s competitors have a beta of 1.07, suggesting that their average stock price is 7% more volatile than the S&P 500.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.